Figure 4.

Kaplan-Meier plots of overall survival and progression-free survival by blood TMB high/low status and PD-L1 expression. (A) OS^a and (B) PFS^b by bTMB-high/low status and PD-L1 expression in the T + D + CT versus CT and D + CT versus CT arms. bTMB, blood tumor mutational burden; CI, confidence interval; CT, chemotherapy; D, durvalumab; HR, hazard ratio; Mb, megabase; mut, mutations; OS, overall survival; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; T, tremelimumab; TC, tumor cell. ^aData cut-off: 12 March 2021. ^bData cut-off: 24 July 2019. HRs and CIs were estimated from an unstratified Cox proportional hazards model.